Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles

Cancer Science

Volumn 100, Issue 10, 2009, Pages 1935-1942

  Yutani, Shigeru ^a,b   Komatsu, Nobukazu ^a,c   Shichijo, Shigeki ^a   Yoshida, Kazumi ^a   Takedatsu, Hiroko ^a   Itou, Minoru ^b   Kuromatu, Ryoko ^b   Ide, Tatsuya ^b   Tanaka, Masatoshi ^b   Sata, Michio ^b   Yamada, Akira ^a,c   Itoh, Kyogo ^c  

^a Department of Immunology and Immunotherapy ^*  (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KURUME UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ALPHA INTERFERON; BETA INTERFERON; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN G; INTERFERON; PEPTIDE VACCINE; RIBAVIRIN; VIRUS RNA;

ACIDOSIS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOGLOBULIN PRODUCTION; INJECTION SITE INFLAMMATION; INTESTINE INFECTION; KIDNEY FAILURE; MALE; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SEPSIS; UNSPECIFIED SIDE EFFECT; VACCINATION;

ADULT; AGED; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS C ANTIGENS; HEPATITIS C, CHRONIC; HLA-A ANTIGENS; HUMANS; IMMUNOGLOBULIN G; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SUBUNIT; VIRAL CORE PROTEINS;

EID: 70349596123     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01256.x     Document Type: Article

References (29)

1. (Website on the internet). 2006, Available from URL: http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.htm l#disease%20burden, World Health Organization, Geneve, Switzerland, cited at July 6, 2009
2. Chander G, Sulkowski MS, Jenckes MW. Treatment of chronic hepatitis C: a systematic review. Hepatol 2002, 36:S135-4.
3. Kato N, Hijikata M, Ootsuyama Y. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 1990, 87:9524-8.
4. Blatt LM, Mutchnick MG, Tong MJ. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat 2000, 7:196-202.
5. Schlaphoff V, Klade CS, Jilma B. Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients. Vaccine 2007, 25:6793-806.
6. Klade CS, Wedemeyer H, Berg T. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 2008, 134:1385-95.
7. Yutani S, Yamada A, Yoshida K. Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy. Vaccine 2007, 25:7429-35.
8. Battegay M, Fikes J, Di Bisceglie AM. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol 1995, 69:2462-70.
9. Cerny A, McHutchison JG, Pasquinelli C. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest 1995, 95:521-30.
10. Matsueda S, Takedatsu H, Sasada T. New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles. J Immunother 2007, 30:274-81.
11. Wang Y, Takao Y, Harada M. New epitope peptides derived from hepatitis C virus (HCV) 2a which have the capacity to induce cytotoxic t lymphocytes in HLA-A2+ HCV-infected patients. Microbiol Immunol 2006, 50:857-65.
12. Takao Y, Yamada A, Yutani S, Sata M, Itoh K. Antibody reactive a hepatitis C virus (HCV)-derived peptide capable of inducing HLA-A2 restricted cytotoxic T lymphocytes is detectable in a majority of HCV-infected individuals without HLA-A2 restriction. Microbiol Immunol 2004, 48:507-17.
13. Matsueda S, Yamada A, Takao Y. A new epitope peptide derived from hepatitis C virus 1b possessing the capacity to induce cytotoxic T-lymphocytes in HCV1b-infected patients with HLA-A11-A31 and -A33. Cancer Immunol Immunother 2007, 56:1359-66.
14. Ogata R, Matsueda S, Yao A, Noguchi M, Itoh K, Harada M. Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptides immunogenic in HLA-A24+ prostate cancer patients. Prostate 2004, 60:273-81.
15. Yamada N, Ishikawa Y, Dumrese T. Role of anchor residues in peptide binding to three HLA-A26 molecules. Tissue Antigens 1999, 54:325-32.
16. Bowen DG, Walker CM. Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man. J Exp Med 2005, 201:1709-14.
17. Rushbrook SM, Ward SM, Unitt E. Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. J Virol 2005, 79:7852-9.
18. Strickland GT, EI-Kamary SS, Klenerman P, Nicosia A. Hepatitis C vaccine: supply and demand. Lancet Infect Dis 2008, 8:379-86.
19. Mine T, Sato Y, Noguchi M. Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res 2004, 10:929-37.
20. Noguchi M, Yao A, Harada M. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer. Prostate 2007, 67:933-42.
21. Yajima N, Yamanaka R, Mine T. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 2005, 11:5900-11.
22. Bertoketti A, Bertoletti A, D'Elios MM. Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology 1997, 112:193-9.
23. McGuinness PH, McGuinness PH, Painter D, Davies S, McCaughan GW. Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection. Gut 2000, 46:260-9.
24. Nelson DR, Lauwers GY, Lau JY, Davis GL. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 2000, 118:655-60.
25. Brière F, Servet-Delprat C, Bridon JM, Saint-Remy JM, Banchereau J. Human interleukin 10 induces naive surface immunoglobulin D+ (sIgD+) B cells to secrete IgG1 and IgG3. J Exp Med 1994, 179:757-62.
26. Defrance T, Vanbervliet B, Brière F, Durand I, Rousset F, Banchereau J. Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. J Exp Med 1992, 175:671-82.
27. Moriya K, Fujie H, Shintani Y. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998, 4:1065-7.
28. Tanaka N, Moriya K, Kiyosawa K, Koike K, Aoyama T. Hepatitis C virus core protein induces spontaneous and persistent activation of peroxisome proliferator-activated receptor alpha in transgenic mice: implications for HCV-associated hepatocarcinogenesis. Int J Cancer 2008, 122:124-31.
29. Imanishi T, Akaza T, Kimura A, Tokunaga K, Gojobori T. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. Proceedings of the Eleventh International Histocompatibility Workshop and Conference 1992, 1065-220. In, Oxford, UK, Oxford University Press